文献速递白血病淋巴瘤

评估来自3项临床试验的230例接受伊布替尼治疗的复发/难治性del(17p)慢性淋巴细胞白血病患者

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
PubMed 文献 · Br J Haematol · 2018-06-05

该整合分析评估了3项伊布替尼研究中230例复发/难治性del(17p)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的结局。中位随访28个月,总缓解率85%,估计30个月无进展生存率和总生存率分别为57%(95%CI 50-64)和69%(95%CI 61-75)。伊布替尼的无进展生存和总生存优于其他疗法。

要点

  • 中位随访28个月,总缓解率85%,估计30个月无进展生存率57%,总生存率69%。
  • 基线有血细胞减少的患者中,61%血红蛋白持续改善,67%血小板持续改善,70%中性粒细胞绝对计数持续改善。
  • 乳酸脱氢酶正常或无巨块病变的患者生存结局最佳。

核心结论

  • 伊布替尼治疗del(17p)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的无进展生存和总生存优于其他疗法。
  • 这些结果进一步证明伊布替尼在难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤人群中具有稳健的临床活性。

研究设计与样本

  • 该整合分析纳入3项伊布替尼研究中的230例复发/难治性del(17p)慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。
  • 患者中位既往治疗线数为2(范围1-12)。
  • 可评估患者中18%有del(11q),79%有未突变IGHV。
  • 中位随访28个月。

主要发现

  • 总缓解率为85%。
  • 估计30个月无进展生存率为57%(95%CI 50-64)。
  • 估计30个月总生存率为69%(95%CI 61-75)。
  • 乳酸脱氢酶正常或无巨块病变的患者生存结局最佳。
  • 基线有血细胞减少的患者中,血红蛋白、血小板计数和中性粒细胞绝对计数持续改善的比例分别为61%、67%和70%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1-12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow-up of 28 months, overall response rate was 85% and estimated 30-month progression-free and overall survival rates were 57% [95% confidence interval (CI) 50-64] and 69% (95% CI 61-75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression-free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult-to-treat CLL/SLL populations.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018. PMID: 29873072. doi:10.1111/bjh.15421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。